Search Results
Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK
Search for other papers by Laura L Gathercole in
Google Scholar
PubMed
Search for other papers by Nikolaos Nikolaou in
Google Scholar
PubMed
Search for other papers by Shelley E Harris in
Google Scholar
PubMed
Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK
Search for other papers by Anastasia Arvaniti in
Google Scholar
PubMed
Search for other papers by Toryn M Poolman in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
Search for other papers by Jonathan M Hazlehurst in
Google Scholar
PubMed
Search for other papers by Denise V Kratschmar in
Google Scholar
PubMed
Search for other papers by Marijana Todorčević in
Google Scholar
PubMed
Search for other papers by Ahmad Moolla in
Google Scholar
PubMed
Search for other papers by Niall Dempster in
Google Scholar
PubMed
Search for other papers by Ryan C Pink in
Google Scholar
PubMed
Search for other papers by Michael F Saikali in
Google Scholar
PubMed
Search for other papers by Liz Bentley in
Google Scholar
PubMed
Search for other papers by Trevor M Penning in
Google Scholar
PubMed
Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Search for other papers by Carolyn L Cummins in
Google Scholar
PubMed
Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, Turku, Finland
Search for other papers by Matti Poutanen in
Google Scholar
PubMed
Search for other papers by Alex Odermatt in
Google Scholar
PubMed
Search for other papers by Roger D Cox in
Google Scholar
PubMed
Search for other papers by Jeremy W Tomlinson in
Google Scholar
PubMed
JM Morton NM Fievet C Kenyon CJ Holmes MC Staels B Seckl JR Mullins JJ 2004 Metabolic syndrome without obesity: hepatic overexpression of 11-hydroxysteroid dehydrogenase type 1 in transgenic mice . PNAS 101 7088 – 7093 . ( https
Search for other papers by Bettina Geidl-Flueck in
Google Scholar
PubMed
Search for other papers by Philipp A Gerber in
Google Scholar
PubMed
Introduction Metabolic health is at risk in societies with an excess supply of energy-dense palatable food and drinks and an everyday life with low physical activity. There is a global epidemic of metabolic syndrome ( Saklayen 2018 ), which
Search for other papers by Gisela Helfer in
Google Scholar
PubMed
Search for other papers by Qing-Feng Wu in
Google Scholar
PubMed
Introduction Adipokines, secreted by adipose tissue, are involved in the pathogenesis of metabolic syndrome ( Lehr et al . 2012 ). Chemerin, encoded by the gene retinoic acid receptor responder 2 ( Rarres2 ), also known as tazarotene
Search for other papers by Thomas Nicholson in
Google Scholar
PubMed
Search for other papers by Chris Church in
Google Scholar
PubMed
Search for other papers by Kostas Tsintzas in
Google Scholar
PubMed
Search for other papers by Robert Jones in
Google Scholar
PubMed
Search for other papers by Leigh Breen in
Google Scholar
PubMed
Search for other papers by Edward T Davis in
Google Scholar
PubMed
Search for other papers by David J Baker in
Google Scholar
PubMed
Search for other papers by Simon W Jones in
Google Scholar
PubMed
reported that the prevalence of metabolic syndrome is higher in females than in males ( Beigh & Jain 2012 ), with central adiposity being a greater risk factor for metabolic diseases in females ( Li et al. 2006 , Holliday et al. 2011 ). Contrary to
Search for other papers by I J Bujalska in
Google Scholar
PubMed
Search for other papers by L L Gathercole in
Google Scholar
PubMed
Search for other papers by J W Tomlinson in
Google Scholar
PubMed
Search for other papers by C Darimont in
Google Scholar
PubMed
Search for other papers by J Ermolieff in
Google Scholar
PubMed
Search for other papers by A N Fanjul in
Google Scholar
PubMed
Search for other papers by P A Rejto in
Google Scholar
PubMed
Search for other papers by P M Stewart in
Google Scholar
PubMed
metabolic syndrome (MS). However, Cushing's syndrome is rare and circulating glucocorticoid levels are usually normal or even slightly reduced in obese patients ( Fraser et al . 1999 ). At a cellular level, glucocorticoids within human adipose tissue
Search for other papers by Lianne Abrahams in
Google Scholar
PubMed
Search for other papers by Nina M Semjonous in
Google Scholar
PubMed
Search for other papers by Phil Guest in
Google Scholar
PubMed
Search for other papers by Agnieszka Zielinska in
Google Scholar
PubMed
Search for other papers by Beverly Hughes in
Google Scholar
PubMed
Search for other papers by Gareth G Lavery in
Google Scholar
PubMed
Search for other papers by Paul M Stewart in
Google Scholar
PubMed
myopathy persisted. GCs can have detrimental effects on metabolic homoeostasis, and therapeutic inhibition of 11β-HSD1 and/or H6PDH has been proposed as a potential strategy to ameliorate a range of disease states such as obesity, metabolic syndrome and
Search for other papers by Taira Wada in
Google Scholar
PubMed
Search for other papers by Yukiko Yamamoto in
Google Scholar
PubMed
Search for other papers by Yukiko Takasugi in
Google Scholar
PubMed
Search for other papers by Hirotake Ishii in
Google Scholar
PubMed
Search for other papers by Taketo Uchiyama in
Google Scholar
PubMed
Search for other papers by Kaori Saitoh in
Google Scholar
PubMed
Search for other papers by Masahiro Suzuki in
Google Scholar
PubMed
Tokyo Adachi Hospital, Adachi, Tokyo, Japan
Search for other papers by Makoto Uchiyama in
Google Scholar
PubMed
Search for other papers by Hikari Yoshitane in
Google Scholar
PubMed
Search for other papers by Yoshitaka Fukada in
Google Scholar
PubMed
Search for other papers by Shigeki Shimba in
Google Scholar
PubMed
et al. 1999 ). Because adiponectin is a crucial factor in the regulation of glucose and lipid metabolism, inflammation, and oxidative stress, reduced adiponectin levels play a causal role in the development of insulin resistance, metabolic syndrome
Search for other papers by Dawn E W Livingstone in
Google Scholar
PubMed
Search for other papers by Sarah L Grassick in
Google Scholar
PubMed
Search for other papers by Gillian L Currie in
Google Scholar
PubMed
Search for other papers by Brian R Walker in
Google Scholar
PubMed
Search for other papers by Ruth Andrew in
Google Scholar
PubMed
supported the hypothesis that variations in glucocorticoid metabolism within target tissues play an important role in the pathophysiology of Metabolic Syndrome. In addition to 11β-HSD1, glucocorticoids are metabolised by several other enzymes ( Fig. 1 ). In
Diabetes Institute, Ohio University, Athens, Ohio, USA
Department of Biological Sciences, Ohio University, Athens, Ohio, USA
Molecular & Cellular Biology Program, College of Arts and Sciences, Ohio University, Athens, Ohio, USA
Search for other papers by Ashley Patton in
Google Scholar
PubMed
Diabetes Institute, Ohio University, Athens, Ohio, USA
Search for other papers by Tyler Church in
Google Scholar
PubMed
Search for other papers by Caroline Wilson in
Google Scholar
PubMed
Diabetes Institute, Ohio University, Athens, Ohio, USA
Search for other papers by Jean Thuma in
Google Scholar
PubMed
Molecular & Cellular Biology Program, College of Arts and Sciences, Ohio University, Athens, Ohio, USA
Biomedical Engineering Program, Ohio University, Athens, Ohio, USA
Search for other papers by Douglas J Goetz in
Google Scholar
PubMed
Department of Biomedical Sciences, Ohio University, Athens, Ohio, USA
The Edison Biotechnology Institute, Ohio University, Athens, Ohio, USA
Search for other papers by Darlene E Berryman in
Google Scholar
PubMed
Diabetes Institute, Ohio University, Athens, Ohio, USA
The Edison Biotechnology Institute, Ohio University, Athens, Ohio, USA
Search for other papers by Edward O List in
Google Scholar
PubMed
Diabetes Institute, Ohio University, Athens, Ohio, USA
Search for other papers by Frank Schwartz in
Google Scholar
PubMed
Diabetes Institute, Ohio University, Athens, Ohio, USA
Department of Biological Sciences, Ohio University, Athens, Ohio, USA
Molecular & Cellular Biology Program, College of Arts and Sciences, Ohio University, Athens, Ohio, USA
Biomedical Engineering Program, Ohio University, Athens, Ohio, USA
Department of Biomedical Sciences, Ohio University, Athens, Ohio, USA
Search for other papers by Kelly D McCall in
Google Scholar
PubMed
). NAFLD, the hepatic manifestation of metabolic syndrome ( Yki-Jarvinen 2014 ), is linked to visceral obesity (a systemic pro-inflammatory state), dyslipidemia, insulin resistance and type 2 diabetes mellitus (T2DM) ( Zelber-Sagi et al . 2006
Search for other papers by Antonio Gázquez in
Google Scholar
PubMed
Search for other papers by Francisca Rodríguez in
Google Scholar
PubMed
Search for other papers by María Sánchez-Campillo in
Google Scholar
PubMed
Search for other papers by Lidia E Martínez-Gascón in
Google Scholar
PubMed
Search for other papers by Marino B Arnao in
Google Scholar
PubMed
Search for other papers by Pedro Saura-Garre in
Google Scholar
PubMed
Search for other papers by María D Albaladejo-Otón in
Google Scholar
PubMed
Search for other papers by Elvira Larqué in
Google Scholar
PubMed
cardiometabolic disease later in life ( Boney et al. 2005 , Lawlor et al. 2010 ), contributing to the perpetuation of the vicious cycle of obesity, diabetes, and metabolic syndrome. There is also growing evidence of the GDM long-term consequences for mothers